<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35337919</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7573</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>292</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of ethnopharmacology</Title>
          <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Baihe Dihuang (Lilium Henryi Baker and Rehmannia Glutinosa) decoction attenuates somatostatin interneurons deficits in prefrontal cortex of depression via miRNA-144-3p mediated GABA synthesis and release.</ArticleTitle>
        <Pagination>
          <StartPage>115218</StartPage>
          <MedlinePgn>115218</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2022.115218</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-8741(22)00257-4</ELocationID>
        <Abstract>
          <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Baihe Dihuang Decoction is a well-known traditional Chinese medicine prescription (Also known as Lilium Henryi Baker and Rehmannia Glutinosa Decoction, LBRD) composed of Lilium Henryi Baker bulb and raw juice from Rehmannia Glutinosa (Gaertn) DC with the curative efficacy of nourishing yin and clearing heat based on the Chinese herbal medicine theory. It has been used as routine medication in treating depression combined with conventional western medicine in China for years.</AbstractText>
          <AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">LBRD can attenuates GABAergic deficits in the medial prefrontal cortex (mPFC) of depression. This study aimed to investigate the mechanism of antidepressive properties of LBRD in the prefrontal GABAergic interneuron subtypes, including parvalbumin (PV), somatostatin (SST), vasoactive intestinal peptide (VIP)-positive neuron.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">In this project, chronic unpredicted mild stress paradigm was adopted to construct depression model. After treated with LBRD standard decoction and behaviors test, the level of GABA associated miRNA/mRNA and GABAergic subtype-specific markers were detected by qRT-PCR and Western blot. The lncRNAs/miRNAs/GABA regulatory axis was verified by luciferase reporter assay, RNA immunoprecipitation, RNA pull-down assay, and theses changes were measured in LBRD administration with the use of immunofluorescence staining and RNA-fluorescence in situ hybridization.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In the current study, we found that LBRD exhibited high efficacy based on the results of behavioral tests. Meanwhile, LBRD also improved the reduced GABA levels in depression by increasing the expression of lncRNA Neat1 and Malat1, as well as decreasing miRNA-144-3p and miRNA-15b-5p. Moreover, the level of Sst mRNA and protein that were harvested from the mPFC tissues of depression group was significantly lower than those in the control mice. While, these changes can be reverted by LBRD standard decoction administration. Whereas, neither chronic stress nor treatment can change the level of PV and VIP mRNAs and protein expression. In the SST-positive neuron of mPFC tissues, treatment with LBRD standard decoction resulted in the elevation of Gad-67, VGAT, GAT-3 and a reduction of miRNA-144-3p expression.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggested that LBRD antidepressant activities may be related to ameliorating the SST-positive neuron deficits via regulating the miRNA-144-3p mediated GABA synthesis and release.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Xiaoyan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Shandong Co-Innovation Center of Classic TCM Formula, Shandong University of Traditional Chinese Medicine, Jinan, 250355, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Jin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Shandong Co-Innovation Center of Classic TCM Formula, Shandong University of Traditional Chinese Medicine, Jinan, 250355, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hongxiu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Shandong Co-Innovation Center of Classic TCM Formula, Shandong University of Traditional Chinese Medicine, Jinan, 250355, PR China; Institute of Virology, Jinan Municipal Center for Disease Control and Prevention, Jinan, 250021, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Yanting</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Shandong Co-Innovation Center of Classic TCM Formula, Shandong University of Traditional Chinese Medicine, Jinan, 250355, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mao</LastName>
            <ForeName>Qiancheng</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Shandong Co-Innovation Center of Classic TCM Formula, Shandong University of Traditional Chinese Medicine, Jinan, 250355, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Ke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Shandong Co-Innovation Center of Classic TCM Formula, Shandong University of Traditional Chinese Medicine, Jinan, 250355, PR China. Electronic address: make@sdutcm.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>J Ethnopharmacol</MedlineTA>
        <NlmUniqueID>7903310</NlmUniqueID>
        <ISSNLinking>0378-8741</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>37221-79-7</RegistryNumber>
          <NameOfSubstance UI="D014660">Vasoactive Intestinal Peptide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>51110-01-1</RegistryNumber>
          <NameOfSubstance UI="D013004">Somatostatin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>56-12-2</RegistryNumber>
          <NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017404" MajorTopicYN="N">In Situ Hybridization, Fluorescence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007395" MajorTopicYN="N">Interneurons</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027762" MajorTopicYN="Y">Lilium</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032267" MajorTopicYN="Y">Rehmannia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013004" MajorTopicYN="N">Somatostatin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014660" MajorTopicYN="N">Vasoactive Intestinal Peptide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Competitive endogenous RNA</Keyword>
        <Keyword MajorTopicYN="N">Depression</Keyword>
        <Keyword MajorTopicYN="N">GABAergic deficits</Keyword>
        <Keyword MajorTopicYN="N">Lily bulb and rehmannia decoction</Keyword>
        <Keyword MajorTopicYN="N">SST interneurons</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>5</Hour>
          <Minute>28</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35337919</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jep.2022.115218</ArticleId>
        <ArticleId IdType="pii">S0378-8741(22)00257-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
